Epidermal growth factor receptors siRNA-conjugated collagen modified gold nanoparticles for targeted imaging and therapy of lung cancer

doi:10.1016/j.mtadv.2021.100191

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24037

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24037

Title:	Epidermal growth factor receptors siRNA-conjugated collagen modified gold nanoparticles for targeted imaging and therapy of lung cancer
Authors:	Yu, AYH;Fu, RH;Hsu, SH;Chiu, CF;Fang, WH;Yeh, CA;Tang, CM;Hsieh, HH;Hung, HS
Keywords:	Epidermal growth factor receptor;Gold nanoparticle (AuNP);Small-interfering RNA (siRNA);Lung cancer
Date:	2021
Issue Date:	2022-08-05T09:46:50Z (UTC)
Publisher:	ELSEVIER
ISSN:	2590-0498
Abstract:	Epidermal growth factor receptor (EGFR), a critical factor promotes lung cancer cell proliferation and survival. Knockdown of EGFR expression thus promise beating lung cancer clinically. Functionalized gold nanoparticles may serve an effective vehicle carrying theranostic bio-active materials. Herein, physically gold nanoparticles were fabricated with biocompatible collagen to improve siRNA loading capacity carrying EGFR siRNA to treat lung cancer. Physic-chemical properties were comprehensively characterized for the collagen gold nanoparticle (C-Au), and with EGFR siRNA conjugation, C-Au-EGFRsi namely. Issues of biocompatibility were addressed. Interestingly, C-Au appeared more biocompatible to normal airway epithelial cells (BEAS-2B) than to cancer cells (A549) in terms of ROS production, cell cycle behavior, and cell growth influence. The C-Au demonstrated comparable or even more efficient, compared with lipofetamine, in carrying siRNA to knockdown EGFR of A549 cells. Endocytosis mediated cell entry for the collagen gold nanoparticles, and endosome-lysosomal pathway involved transporting and metabolizing these nanoparticles. In xenograft mice model, substantial tumor suppression effects were observed treating with C-Au-EGFRsi, in which tumor weight reduced 30% for lipofetamine carrier, and down to 70% for C-Au carrier. Particularly, overall survival rate was improved for both treatment groups with lipofetamine and C-Au carrier, respectively. (c) 2021 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
URI:	http://dx.doi.org/10.1016/j.mtadv.2021.100191 https://www.webofscience.com/wos/woscc/full-record/WOS:000744197600005 https://ir.csmu.edu.tw:8080/handle/310902500/24037
Relation:	MATERIALS TODAY ADVANCES ,2021,v12
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	199	View/Open

Loading...